Stock Events

Stock Events

Rakovina Therapeutics 

€0.04
8
+€0+0% Wednesday 07:59

Statistics

Day High
0.04
Day Low
0.04
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

27AugExpected
Q1 2025
Q2 2025
-0.12
0.21
0.55
0.88
Expected EPS
N/A
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2021
2022
2023
2024
0Revenue
-2.75MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 7JO.F. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Merck
MRK
Mkt Cap276.38B
Merck & Co., Inc. develops oncology drugs, directly competing in cancer treatment advancements.
Bristol-Myers Squibb
BMY
Mkt Cap119.87B
Bristol-Myers Squibb is involved in developing cancer therapies, overlapping with Rakovina's focus areas.
Pfizer
PFE
Mkt Cap153.59B
Pfizer Inc. has a significant portfolio in oncology, competing in the cancer treatment market.
Lilly(Eli) &
LLY
Mkt Cap789.69B
Eli Lilly and Company develops therapies for various cancers, directly competing with Rakovina's cancer focus.
Astrazeneca
AZN
Mkt Cap294.17B
AstraZeneca PLC has a strong presence in the oncology sector, making it a direct competitor.
Gilead Sciences
GILD
Mkt Cap161.85B
Gilead Sciences, Inc. focuses on oncology among other areas, competing in the cancer drug market.
AMGEN
AMGN
Mkt Cap185.74B
Amgen Inc. develops and markets oncology drugs, competing in the same therapeutic areas as Rakovina.
Regeneron Pharmaceuticals
REGN
Mkt Cap79.46B
Regeneron Pharmaceuticals, Inc. is known for its cancer biologics, competing in oncology.
Novartis
NVS
Mkt Cap280.79B
Novartis AG has extensive research and development in oncology, aligning as a competitor in cancer treatment.
Johnson & Johnson
JNJ
Mkt Cap547.64B
Johnson & Johnson engages in the development of oncology treatments, competing in the pharmaceutical and biotech sector for cancer therapies.

About

Rakovina Therapeutics Inc., a biopharmaceutical research company, engages in the research and development of cancer treatments based on novel series of small-molecule DNA-damage response targets. The company's preclinical product pipeline include kt-2000AI, an poly(ADP)-ribose polymerase (PARP) brain penetrant cancer therapy; kt-3000, a bi-functional small-molecule drug candidate; kt-3283 series for the treatment of PARP resistant adult and childhood cancers; and kt-4000, a DNA-damaging DDR inhibitors. It has a research collaboration with Variational AI Inc. to identify and develop novel small-molecule therapies against DNA-damage response (DDR) targets for the treatment of cancer. Additionally, it signed a letter of intent with NanoPalm Ltd. to form a joint venture to co-develop novel small-molecule oncology therapeutics. The company was formerly known as Vincero Capital Corp. Rakovina Therapeutics Inc. is headquartered in Vancouver, Canada.
Show more...
CEO
Dr. Mads Daugaard Ph.D.
Country
Canada
ISIN
CA75103L1013
WKN
000A3DJYB

Listings

F
DE
7JO0.F
STU
DE
7JO0.STU
MU
DE
7JO0.MU
OTC Link
US
RKVTF

0 Comments

Share your thoughts

FAQ

What is Rakovina Therapeutics stock price today?▼
The current price of 7JO.F is €0.04 EUR — it has increased by +0% in the past 24 hours. Watch Rakovina Therapeutics stock price performance more closely on the chart.
What is Rakovina Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Rakovina Therapeutics stocks are traded under the ticker 7JO.F.
Is Rakovina Therapeutics stock price growing?▼
7JO.F stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year Rakovina Therapeutics has showed a +12.73% increase.
What is Rakovina Therapeutics revenue for the last year?▼
Rakovina Therapeutics revenue for the last year amounts to 0 EUR.
What is Rakovina Therapeutics net income for the last year?▼
7JO.F net income for the last year is -2.75M EUR.
In which sector is Rakovina Therapeutics located?▼
Rakovina Therapeutics operates in the Health & Wellness sector.
When did Rakovina Therapeutics complete a stock split?▼
Rakovina Therapeutics has not had any recent stock splits.
Where is Rakovina Therapeutics headquartered?▼
Rakovina Therapeutics is headquartered in Vancouver, Canada.